Biotech startups that raised Series A in Massachusetts, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Arkea Bio | Charlestown | Series A | $15.0M | 2026-09-29 |
| Remedium Bio | Needham | Series A | $10.0M | 2026-08-10 |
| Dash Bio | Boston | Series A | $30.0M | 2026-08-03 |
| Xellar Biosystems | Newton | Series A | $29.5M | 2026-06-30 |
| Stata DX | Cambridge | Series A | $400K | 2026-02-27 |
| Third Arc Bio | Boston | Series A | $52.0M | 2026-02-04 |
| Prudentia Sciences | Cambridge | Series A | $20.0M | 2026-01-07 |
| Neurable | Boston | Series A | $35.0M | 2025-12-19 |
8 rows of the CSV in 5 of its 18 columns.
- The 223 biotech startups in Massachusetts, United States whose last round is Series A have raised $10.9B in total.
- 31 of them closed their most recent round in the last 12 months, $1.3B combined.
- The largest of those rounds is Solstice Oncology's $225.0M Series A, dated September 2026.
- The most recent is Signet Therapeutics' $11.5M Series A on 4 November 2026.
- MassChallenge is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 196 companies (88%).
- 38% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (59% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
25 of 223| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Arkea Bio | Arkea Bio develops technology that reduces greenhouse gas emissions from agriculture. | Biotech | Charlestown | Series A | $15.0M | 2026-09-29 | $60.5M | Breakthrough Energy Ventures, Overview, Rabo Ventures | 11 to 50 | 2021 |
| Remedium Bio | Remedium Bio develops gene therapy treatments for various diseases. | Biotech | Needham | Series A | $10.0M | 2026-08-10 | $13.8M | National Science Foundation, MicroVentures, Longevitytech.fund +1 | 11 to 50 | 2020 |
| Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Boston | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| Xellar Biosystems | Xellar Biosystems analyzes drug testing and treatment data using artificial intelligence. | Artificial intelligence | Newton | Series A | $29.5M | 2026-06-30 | $93.2M | Legend Capital, Tiantu Capital, Zhengxuan Investment +1 | 11 to 50 | 2022 |
| Stata DX | Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. | Biotech | Cambridge | Series A | $400K | 2026-02-27 | $3.6M | MassVentures | 1 to 10 | 2022 |
| Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Boston | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Cambridge | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Boston | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| AI Proteins | AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. | Artificial intelligence | Boston | Series A | $42.5M | 2025-11-19 | $80.4M | Intel Ignite, Lightchain Capital, Cobro Ventures | 11 to 50 | 2021 |
| Folia Health | Folia Health is a platform that securely captures and shares users' health and symptom data. | Biotech | Boston | Series A | $10.5M | 2025-10-01 | $17.4M | MassChallenge, Social Starts, Bantam Group +2 | 11 to 50 | 2016 |
| Biobot Analytics | Biobot Analytics offers a wastewater data platform that delivers population-level health insights. | Artificial intelligence | Cambridge | Series A | $13.4M | 2025-06-06 | $41.4M | Y Combinator, Pioneer Fund, Soma Capital +2 | 11 to 50 | 2017 |
| Progentos Therapeutics | Progentos Therapeutics develops a multiple sclerosis treatment that stimulates the body's natural repair mechanisms. | Biotech | Watertown | Series A | $65.0M | 2024-05-14 | $65.0M | Forbion Capital Partners, Dolby Family Ventures, Alta Partners +2 | 11 to 50 | 2023 |
| Nabla Bio | Nabla Bio uses an autoverse platform of biologically informed machine learning to co-develop antibody drugs. | Artificial intelligence | Cambridge | Series A | $26.0M | 2024-05-14 | $37.4M | Y Combinator, Khosla Ventures, National Science Foundation +2 | 11 to 50 | 2020 |
| Adaptilens | Adaptilens develops an accommodating intraocular lens for cataract patients. | Biotech | Boston | Series A | $17.5M | 2024-04-29 | $19.1M | MassChallenge, Pillar VC, Perceptive Advisors +2 | 1 to 10 | 2019 |
| Corner Therapeutics | Corner Therapeutics conducts biotechnology research focused on immunotherapy. | Biotech | Watertown | Series A | $58.5M | 2024-04-18 | $58.5M | Bill & Melinda Gates Foundation, Ziff Capital Partners, Tanis ventures | 11 to 50 | 2020 |
| Edgewood Oncology | Edgewood Oncology develops a first-in-class therapy for hard-to-treat cancers. | Biotech | Brookline | Series A | $20.0M | 2024-03-25 | $20.0M | Alta Partners | 1 to 10 | 2023 |
| Tome Biosciences | Tome Biosciences develops programmable gene insertion technology. | Biotech | Watertown | Series A | $213.0M | 2023-12-12 | $213.0M | Andreessen Horowitz, Google Ventures, Polaris Partners +1 | 101 to 250 | 2021 |
| Ascidian Therapeutics | Ascidian Therapeutics is a biotechnology company focused on medical and clinical gene therapy. | Biotech | Boston | Series A | $40.0M | 2023-11-08 | $90.0M | Apple Tree Partners | 11 to 50 | 2020 |
| i2o Therapeutics | I2o Therapeutics is a biotech company that develops safe, effective oral formulations of therapies. | Biotech | Allston | Series A | $46.0M | 2023-08-28 | $90.4M | Cerity Partners Ventures, Viva BioInnovator, Sanofi Ventures +1 | 11 to 50 | 2019 |
| Luminopia | Luminopia develops digital treatments for significant neuro-visual disorders. | Biotech | Cambridge | Series A | $16.0M | 2023-06-27 | $33.1M | MassChallenge, U.S. Venture Partners, Bantam Group +2 | 11 to 50 | 2015 |
| Sealonix | Sealonix develops and commercializes hemostatic sealants made from proprietary biomaterials. | Biotech | Bedford | Series A | $20.0M | 2023-05-12 | $20.0M | J2 Ventures, Excelestar Ventures, AMED Ventures +2 | 11 to 50 | 2023 |
| Dyno Therapeutics | Dyno Therapeutics uses artificial intelligence to develop gene therapies. | Artificial intelligence | Cambridge | Series A | $100.0M | 2021-05-06 | $109.0M | Andreessen Horowitz, Google Ventures, CRV +2 | 101 to 250 | 2018 |
| Orbita | Orbita sells voice-first and conversational AI software that helps patients engage with digital healthcare. | Artificial intelligence | Boston | Series A | $9.0M | 2020-05-27 | $16.5M | MassChallenge, nvp capital, Cultivation Capital +2 | 11 to 50 | 2015 |
| Horsepower Technologies | Horsepower Technologies develops orthotic devices for horses in animal healthcare. | Biotech | Lowell | Series A | $350K | 2018-07-02 | $9.4M | Alumni Ventures, MassVentures, Green D Ventures +2 | 11 to 50 | 2008 |
| Brontes Technologies | Brontes Technologies develops dental imaging technology. | Biotech | Lexington | Series A | $7.0M | 2004-05-05 | $7.0M | Flybridge | 11 to 50 | 2003 |
Table 1. Biotech startups that raised Series A in Massachusetts, United States: the 25 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 223.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Boston | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| 2 | AI Proteins | AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. | Artificial intelligence | Boston | Series A | $42.5M | 2025-11-19 | $80.4M | Intel Ignite, Lightchain Capital, Cobro Ventures | 11 to 50 | 2021 |
| 3 | Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Boston | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| 4 | Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Boston | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| 5 | Xellar Biosystems | Xellar Biosystems analyzes drug testing and treatment data using artificial intelligence. | Artificial intelligence | Newton | Series A | $29.5M | 2026-06-30 | $93.2M | Legend Capital, Tiantu Capital, Zhengxuan Investment +1 | 11 to 50 | 2022 |
| 6 | Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Cambridge | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| 7 | Arkea Bio | Arkea Bio develops technology that reduces greenhouse gas emissions from agriculture. | Biotech | Charlestown | Series A | $15.0M | 2026-09-29 | $60.5M | Breakthrough Energy Ventures, Overview, Rabo Ventures | 11 to 50 | 2021 |
| 8 | Remedium Bio | Remedium Bio develops gene therapy treatments for various diseases. | Biotech | Needham | Series A | $10.0M | 2026-08-10 | $13.8M | National Science Foundation, MicroVentures, Longevitytech.fund +1 | 11 to 50 | 2020 |
| 9 | Stata DX | Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. | Biotech | Cambridge | Series A | $400K | 2026-02-27 | $3.6M | MassVentures | 1 to 10 | 2022 |
Table 2. Biotech startups that raised Series A in Massachusetts, United States: the 9 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | MassChallenge | Startup accelerator | Boston, United States | 4 | 2% | ||
| 2 | Y Combinator | Startup accelerator | Mountain View, United States | 4 | 2% | ||
| 3 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 3 | 1% | 2 | Remedium Bio, Neurable |
| 4 | Google Ventures | Corporate venture arm | San Francisco, United States | 3 | 1% | 1 | Prudentia Sciences |
| 5 | MassVentures | Venture capital firm | Boston, United States | 2 | 1% | 1 | Stata DX |
| 6 | Foresite Capital | Private equity firm | San Francisco, United States | 2 | 1% | 1 | Third Arc Bio |
| 7 | Bantam Group | Angel group | Westwood, United States | 2 | 1% | ||
| 8 | Soma Capital | Venture capital firm | San Francisco, United States | 2 | 1% | ||
| 9 | Pillar VC | Venture capital firm | Boston, United States | 2 | 1% | ||
| 10 | Apple Tree Partners | Venture capital firm | New York, United States | 2 | 1% | ||
| 11 | Alta Partners | Venture capital firm | Jackson, United States | 2 | 1% | ||
| 12 | Longwood Fund | Venture capital firm | Boston, United States | 2 | 1% | ||
| 13 | Alumni Ventures | Angel group | Manchester, United States | 2 | 1% | ||
| 14 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 2 | 1% | ||
| 15 | Polaris Partners | Private equity firm | Boston, United States | 2 | 1% |
Table 3. Biotech startups that raised Series A in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 196 | 88% | $10.1B |
| Software | 32 | 14% | $1.1B |
| Artificial intelligence | 22 | 10% | $773.2M |
| Hardware | 7 | 3% | $174.9M |
| Commerce | 2 | 1% | $20.6M |
| Education | 1 | 0% | $12.7M |
| Energy | 1 | 0% | $5.8M |
Table 4. Biotech startups that raised Series A in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 223 | 100% | $26.0M |
Table 5. Biotech startups that raised Series A in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups that raised Series A in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 3% | $11.5M |
| October 2026 | 1 | 3% | $30.0M |
| September 2026 | 5 | 16% | $306.3M |
| August 2026 | 3 | 10% | $70.0M |
| July 2026 | 1 | 3% | $21.0M |
| June 2026 | 4 | 13% | $93.1M |
| April 2026 | 3 | 10% | $260.0M |
| March 2026 | 2 | 6% | $61.0M |
| February 2026 | 2 | 6% | $52.4M |
| January 2026 | 4 | 13% | $137.5M |
| December 2025 | 3 | 10% | $102.5M |
| November 2025 | 2 | 6% | $132.5M |
Table 7. Biotech startups that raised Series A in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 26 | 12% | $1.0B |
| 2025 | 24 | 11% | $1.3B |
| 2024 | 19 | 9% | $997.5M |
| 2023 | 17 | 8% | $1.1B |
| 2022 | 22 | 10% | $898.9M |
| 2021 | 32 | 14% | $1.1B |
Table 8. Biotech startups that raised Series A in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 19 | 9% |
| 2020 to 2022 | 66 | 30% |
| 2015 to 2019 | 78 | 35% |
| 2010 to 2014 | 30 | 14% |
| Before 2010 | 28 | 13% |
Table 9. Biotech startups that raised Series A in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 72 | 32% |
| 11 to 50 | 130 | 59% |
| 51 to 100 | 8 | 4% |
| 101 to 250 | 9 | 4% |
| 251 to 500 | 2 | 1% |
| 10,001 or more | 1 | 0% |
Table 10. Biotech startups that raised Series A in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in Massachusetts, United States. On 16 November 2026 that is 223 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 25 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 223 rows: 22 have no round amount, 0 no city and 32 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Massachusetts, United States whose last round is Series A are on the list?
- 223, in the file dated 16 November 2026. 31 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 223 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.